These two authors equally contributed to this work.
1349-7006/asset/cas_centre.gif?v=1&s=11108c6693d2a39ca49ee937260cc26f94293b0d)
1349-7006/asset/cas_right.gif?v=1&s=8b26cd26c2b4c8264011a9ddc0ed1cf4aaee0b20)
You have free access to this content
Mutational complex genotype of the hepatitis B virus X /precore regions as a novel predictive marker for hepatocellular carcinoma
Article first published online: 19 JAN 2012
DOI: 10.1111/j.1349-7006.2011.02170.x
© 2011 Japanese Cancer Association
Additional Information
How to Cite
Jang, J. W., Chun, J.-Y., Park, Y. M., Shin, S.-K., Yoo, W., Kim, S.-O. and Hong, S. P. (2012), Mutational complex genotype of the hepatitis B virus X /precore regions as a novel predictive marker for hepatocellular carcinoma. Cancer Science, 103: 296–304. doi: 10.1111/j.1349-7006.2011.02170.x
- †
These two authors equally contributed to this work.
Publication History
- Issue published online: 1 FEB 2012
- Article first published online: 19 JAN 2012
- Accepted manuscript online: 2 DEC 2011 09:44AM EST
- (Received October 20, 2011/Revised November 10, 2011/Accepted November 14, 2011/Accepted manuscript online December 2, 2011)
- Abstract
- Article
- References
- Supporting Information
- Cited By
Fig. S1. Prevalence of hepatocellular carcinoma (HCC) according to the number of mutations in the X/precore regions of hepatitis B virus (HBV), showing low, intermediate and high risk for patients with mutations ≤2, 3–5 and ≥6, respectively.
Fig. S2. Proportion of individual mutations at each number of mutations in the X/precore regions.
Fig. S3. Comparison of distribution in the mutational combination patterns between hepatocellular carcinoma (HCC) and non-HCC groups.
Fig. S4. Comparison of sensitivity and specificity for hepatocellular carcinoma (HCC) detection between α-fetoprotein and mutation numbers by ROC.
Table S1. Sequence of primers in this study.
Table S2. Comparison of frequencies between hepatocellular carcinoma (HCC) and non-HCC groups in each pattern of the 55 mutational combination patterns.
Table S3. Linear increasing trend of the proportion of cases with α-fetoprotein (AFP) ≥ 20 ng/mL in serum according to the number of accumulated mutations in total cases (n = 150).
Table S4. Validation analysis using hepatitis B virus (HBV) DNA sequences registered in the GenBank database.
Data S1. Polymerase chain reaction for restriction fragment mass polymorphism (RFMP) assay.
| Filename | Format | Size | Description |
|---|---|---|---|
| CAS_2170_sm_DataS1-FigS1-S4-TableS1-S4.doc | 642K | Supporting info item |
Please note: Wiley-Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.